Latest news with #OneSource
Business Wire
23-06-2025
- Business
- Business Wire
Ausdia Solves Critical Design Flow Gap with OneSource Constraint Translation at DAC 2025
SAN FRANCISCO--(BUSINESS WIRE)-- Ausdia, the leading provider of design constraints verification and management solutions, today introduced Timevision TM OneSource, at DAC 2025, the Chips to Systems Conference. Timevision OneSource addresses a critical challenge facing modern SoC design teams while maintaining the integrity and usability of hand-crafted timing constraints after optimization tools perform aggressive transformations on chip designs. The OneSource technology addresses the fundamental challenge created by modern optimization engines that dissolve hierarchies, restructure interfaces, duplicate elements, and perform advanced transformations like flop banking and cloning. These optimizations, while delivering significant PPA improvements, render original programmatic SDC constraints unusable in their original form. "The shift-left methodology has led design teams to create sophisticated, programmable constraint files that map correctly and consistently on their original RTL designs," said Sam Appleton, Ausdia CEO. "However, when optimization tools restructure hierarchies, merge flops, and clone elements to achieve better PPA, those golden constraints no longer map to the transformed design. OneSource solves this critical gap by automatically translating source constraints to work seamlessly with post-optimization netlists." Automated Constraint Translation Without Manual Intervention Timevision OneSource enables design teams to retain their golden, hand-written SDC constraints throughout the entire design flow. The technology automatically generates a new version of block-level constraints that can be used for full-chip signoff, eliminating the time-consuming and error-prone manual constraint adaptation process that is plaguing post-optimization flows. OneSource maintains two critical capabilities that design teams require: Porting source-form constraints so engineers have full confidence in their signoff checks, and automatically generating chip-level constraints for the post-optimization database without designer intervention. Key Benefits of OneSource: Automated translation: Eliminates manual constraint adaptation after optimization Source preservation: Maintains readable, understandable constraint files for design signoff Full-chip compatibility: Automatically generates constraints compatible with post-optimization netlists Quality assurance: Provides verification and validation of constraint translation accuracy Design flow integration: Seamlessly bridges pre- and post-optimization environments "OneSource represents a breakthrough in constraint management technology," Appleton said. "Design teams no longer need to choose between achieving optimal PPA through advanced optimization and maintaining clean, understandable constraints. Our solution delivers both automatically." Comprehensive Integration with Timevision Platform OneSource integrates seamlessly with the existing Timevision platform, leveraging its comprehensive timing constraints development, verification, and management capabilities. The platform continues to support more than 1 billion cells and thousands of clocks, integrating with all aspects of the design flow from pre-synthesis through signoff timing. About Timevision Ausdia's Timevision platform offers a unique approach to timing constraints development and management, addressing key challenges in AI and large SoC designs, including memory consumption and performance optimization. Ausdia is showcasing the enhanced Timevision platform, including the new OneSource technology, in booth #2429 at DAC, The Chips to Systems Conference, held at Moscone West, San Francisco, from June 22-25 2025. About Ausdia Founded in 2006 and headquartered in Sunnyvale, California, Ausdia delivers standout timing constraint development, verification, and management solutions that complement all implementation and timing signoff flows. Ausdia's customers include leading semiconductor companies worldwide, and the company's solutions are used extensively in the development of SoCs and ICs for AI, HPC, and automotive. For more information, visit Ausdia's website. Ausdia acknowledges trademarks or registered trademarks of other organizations for their respective products and services.
&w=3840&q=100)
Business Standard
12-06-2025
- Business
- Business Standard
OneSource eyes weight-loss drug boost to order book
Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top executive said on Monday. Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk and U.S.-based Eli Lilly. The active chemical compound in Novo's injectable Wegovy drug, semaglutide, will go off patent in 2026 in a few markets, including India. OneSource, which added 15 orders related to obesity and diabetes drugs in fiscal year 2025, said there are more in the pipeline. The global obesity market is estimated to be valued at $150 billion by the early 2030s. The company develops and manufactures complex biological drugs, vials, injectables, and soft gelatin capsules for larger pharmaceutical firms. "Our growth over the next few years will be driven by commercial launches of GLP-1s (weight-loss and diabetes drugs) by our global customers in all the key markets opening post patent expiry in 2026," CEO Neeraj Sharma told Reuters in an interview. Backed by increasing demand from weight-loss drug manufacturers, OneSource's order book across all service verticals should expand in line with 30% compound annual growth rate through fiscal year 2028, according to the CEO. OneSource, which competes with larger players such as Piramal Pharma and Divi's in contract research, development and manufacturing, is investing about $100 million to expand its drug device facilities, the CEO said. The company, which was demerged from Strides Pharma Science and listed in January, is also looking at setting up a global footprint in manufacturing, both in Europe and the U.S. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Reuters
12-06-2025
- Business
- Reuters
India's OneSource eyes weight-loss drug boost to order book
June 12 (Reuters) - Indian contract drug manufacturer OneSource Specialty Pharma ( opens new tab expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top executive said on Monday. Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk ( opens new tab and U.S.-based Eli Lilly (LLY.N), opens new tab. The active chemical compound in Novo's injectable Wegovy drug, semaglutide, will go off patent in 2026 in a few markets, including India. OneSource, which added 15 orders related to obesity and diabetes drugs in fiscal year 2025, said there are more in the pipeline. The global obesity market is estimated to be valued at $150 billion by the early 2030s. The company develops and manufactures complex biological drugs, vials, injectables, and soft gelatin capsules for larger pharmaceutical firms. "Our growth over the next few years will be driven by commercial launches of GLP-1s (weight-loss and diabetes drugs) by our global customers in all the key markets opening post patent expiry in 2026," CEO Neeraj Sharma told Reuters in an interview. Backed by increasing demand from weight-loss drug manufacturers, OneSource's order book across all service verticals should expand in line with 30% compound annual growth rate through fiscal year 2028, according to the CEO. OneSource, which competes with larger players such as Piramal Pharma ( opens new tab and Divi's ( opens new tab in contract research, development and manufacturing, is investing about $100 million to expand its drug device facilities, the CEO said. The company, which was demerged from Strides Pharma Science ( opens new tab and listed in January, is also looking at setting up a global footprint in manufacturing, both in Europe and the U.S.
Yahoo
12-06-2025
- Business
- Yahoo
India's OneSource eyes weight-loss drug boost to order book
By Rishika Sadam (Reuters) -Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top executive said on Monday. Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk and U.S.-based Eli Lilly. The active chemical compound in Novo's injectable Wegovy drug, semaglutide, will go off patent in 2026 in a few markets, including India. OneSource, which added 15 orders related to obesity and diabetes drugs in fiscal year 2025, said there are more in the pipeline. The global obesity market is estimated to be valued at $150 billion by the early 2030s. The company develops and manufactures complex biological drugs, vials, injectables, and soft gelatin capsules for larger pharmaceutical firms. "Our growth over the next few years will be driven by commercial launches of GLP-1s (weight-loss and diabetes drugs) by our global customers in all the key markets opening post patent expiry in 2026," CEO Neeraj Sharma told Reuters in an interview. Backed by increasing demand from weight-loss drug manufacturers, OneSource's order book across all service verticals should expand in line with 30% compound annual growth rate through fiscal year 2028, according to the CEO. OneSource, which competes with larger players such as Piramal Pharma and Divi's in contract research, development and manufacturing, is investing about $100 million to expand its drug device facilities, the CEO said. The company, which was demerged from Strides Pharma Science and listed in January, is also looking at setting up a global footprint in manufacturing, both in Europe and the U.S. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Standard
11-06-2025
- Business
- Business Standard
OneSource collaborates with Xbrane Biopharma AB
For commercial manufacturing of Xbrane's biosimilar portfolio OneSource Specialty Pharma and Xbrane Biopharma AB, a Sweden-headquartered biotechnology company, today announced a partnership focused on the commercial manufacturing of Xbrane's biosimilar portfolio. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference products. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSource's state-of the-art integrated Drug Substance and Drug Product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbrane's global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbrane's latest funding round, reinforcing the long-term alignment between the two companies.
